Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin G P
Istituto di Radiologia, Università degli Studi di Padova, Italy.
J Clin Gastroenterol. 1999 Jun;28(4):334-40. doi: 10.1097/00004836-199906000-00010.
We evaluated factors affecting long-term survival after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) complicating cirrhosis. One hundred eighty-two patients with Child's class A or B cirrhosis and an HCC, not amenable to surgery or percutaneous ethanol injection, underwent 346 TACEs (mean 1.9) with epirubicin, iodized oil, and gelatin sponge. Many prognostic factors were subjected to univariate analysis and thereafter, when significant, to the Cox's hazard proportional model. Finally, the significant indices in the Cox's model were used to estimate the accuracy of the probability of death with computation of the area under the receiving operative characteristic (ROC) curve. The cumulative survival rates at 1, 2, 3, and 5 years were 0.83, 0.52, 0.40, and 0.16, respectively. According to Cox's model, the factors associated with significantly worse survival were the presence of ascites (p = 0.0027), elevated bilirubin levels (p = 0.0163), elevated alpha-fetoprotein (alphaFP) values (p = 0.0067), a tumor greater than 5 cm in diameter (p = 0.0001), and the absence of a tumor capsule-like rim (p = 0.0278). According to these parameters, the accuracy of the probability of death estimated with ROC analysis was 0.63. Minor and major complications occurred in 82 patients (45%) and caused death in 2 patients. Long-term prognosis after TACE for HCCs in patients with Child's class A or B cirrhosis depends on the presence of ascites, the bilirubin level, the alphaFP value, the diameter of the tumor, and the presence of a tumor capsule-like rim. However, when considered altogether, these variables are poor predictors to evaluate survival, and other factors should be investigated to identify subjects more responsive to TACE. Complications occur in a high percentage of patients, but they do not affect long-term prognosis.
我们评估了影响经动脉化疗栓塞术(TACE)治疗合并肝硬化的肝细胞癌(HCC)后长期生存的因素。182例Child A或B级肝硬化合并HCC且不适合手术或经皮乙醇注射治疗的患者接受了346次TACE治疗(平均1.9次),使用表柔比星、碘化油和明胶海绵。对许多预后因素进行单因素分析,之后,当因素具有显著性时,将其纳入Cox风险比例模型。最后,使用Cox模型中的显著指标,通过计算接受手术特征(ROC)曲线下面积来估计死亡概率的准确性。1年、2年、3年和5年的累积生存率分别为0.83、0.52、0.40和0.16。根据Cox模型,与生存率显著较差相关的因素包括腹水的存在(p = 0.0027)、胆红素水平升高(p = 0.0163)、甲胎蛋白(alphaFP)值升高(p = 0.0067)、直径大于5 cm的肿瘤(p = 0.0001)以及无肿瘤包膜样边缘(p = 0.0278)。根据这些参数,ROC分析估计的死亡概率准确性为0.63。82例患者(45%)发生了轻微和严重并发症,2例患者因并发症死亡。Child A或B级肝硬化患者的HCC经TACE治疗后的长期预后取决于腹水的存在、胆红素水平、alphaFP值、肿瘤直径以及肿瘤包膜样边缘的存在。然而,综合考虑这些变量时,它们作为评估生存的预测指标较差,应研究其他因素以识别对TACE反应更敏感的患者。并发症在高比例患者中发生,但不影响长期预后。